Hair Cloning Research: When Will It Be Available?

The concept is straightforward: take a small number of hair follicle cells from a patient, multiply them in a laboratory, and reimplant millions of new follicle-generating cells back into bald scalp. If it works, hair cloning (more accurately called hair follicle neogenesis or dermal papilla cell multiplication) would eliminate the biggest limitation of hair transplants, which is a finite donor supply. Instead of redistributing existing follicles from the back of the head, clinicians could manufacture new ones. Multiple research teams and biotech companies are working on this right now. But a gap of several years still separates laboratory breakthroughs from something your dermatologist can offer.

Track your current treatment while the science advances

Hair cloning is years away. HairLossTracker helps you document and compare results from today's proven treatments so you enter the next era of hair restoration with a complete visual history.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first

What hair cloning actually means

Hair cloning does not mean cloning a person. It refers to multiplying the specific cells responsible for generating hair follicles: dermal papilla (DP) cells. These cells sit at the base of every hair follicle and send signals that instruct surrounding skin cells to form a new hair shaft during each growth cycle. In a healthy follicle, DP cells orchestrate the anagen (growth) phase. In androgenetic alopecia, DP cells in susceptible areas gradually lose their signaling capacity under the influence of DHT, leading to follicle miniaturization.

The goal of hair cloning is to extract DP cells, expand their numbers in culture, and then inject or implant them into bald or thinning scalp. Each cluster of reimplanted DP cells would theoretically induce the surrounding tissue to form a brand-new hair follicle. One small biopsy could, in principle, yield enough cells to restore an entire bald scalp.

The core scientific challenge

Researchers have understood the concept for decades. The obstacle is execution. Higgins et al. (2013, Proceedings of the National Academy of Sciences) demonstrated the central problem: when you remove human dermal papilla cells from a follicle and culture them on a flat (2D) surface in a standard lab dish, they rapidly lose their hair-inductive properties. Within a few passages of cell division, the genes responsible for hair induction switch off. You end up with a dish full of cells that look like generic fibroblasts and can no longer instruct skin to form hair.

This is not a minor technical detail. It is the single biggest bottleneck in the entire field. Every research team working on hair cloning is essentially trying to solve the same problem: how do you expand DP cells in large numbers while keeping their hair-inductive signature intact?

Current research approaches

3D spheroid cultures (Columbia University)

The Higgins lab at Columbia discovered that growing DP cells in 3D clusters (spheroids) rather than on flat surfaces partially preserves their inductive properties. When human DP cells are allowed to aggregate into three-dimensional papilla-like structures in hanging-drop culture, they reactivate many of the genes lost in 2D. The same 2013 PNAS study showed that these 3D spheroids could induce new hair growth when implanted between the dermis and epidermis of human skin grafted onto mice. This was a landmark proof-of-concept, but the efficiency was low and the hairs produced were not cosmetically viable for clinical use.

Organoid-based approaches (Tsuji lab, RIKEN Japan)

The Tsuji laboratory at RIKEN has taken a different approach: building complete hair follicle organoids from scratch. In 2022, the team published results showing they could generate functional hair follicles from mouse embryonic skin cells in culture. These organoids contained all the major components of a natural follicle (dermal papilla, sebaceous glands, arrector pili muscles) and produced pigmented hair shafts when transplanted into nude mice. The achievement was significant because previous attempts had produced simplified follicle-like structures, not fully organized ones.

The limitation: this work used mouse embryonic cells, not adult human cells. Translating the protocol to adult human tissue is a major step that has not yet been completed. Mouse cells behave differently from human cells in culture, and embryonic cells have far greater plasticity than adult cells. The Tsuji lab is actively working on this translation.

iPSC-derived hair follicle cells (dNovo Bio)

dNovo Bio (formerly Stemson Therapeutics), led by Karl Koehler, is using induced pluripotent stem cells (iPSCs) to generate hair follicle cells. iPSCs are adult cells (typically from blood or skin) that have been reprogrammed back to an embryonic-like state, giving them the ability to differentiate into virtually any cell type. The company's approach is to guide iPSCs through a series of differentiation steps that mimic how hair follicles form during embryonic development.

In preclinical work, dNovo has reported generating hair-bearing skin organoids from human iPSCs that produce follicles when grafted onto mice. The iPSC approach has a key advantage: it bypasses the DP cell expansion problem entirely. Instead of trying to multiply existing DP cells without losing their properties, you create fresh DP-like cells from a renewable source. The challenge is ensuring the iPSC-derived cells form follicles that produce cosmetically acceptable hair (correct thickness, color, growth angle) in human scalp tissue.

Wound-induced hair neogenesis (Verteporfin research)

A different angle on hair regeneration emerged from wound healing research. Abbasi et al. (2020, Nature) found that blocking mechanical tension signaling in healing wounds (using the drug Verteporfin, which inhibits the YAP/TAZ pathway) could cause wounds to regenerate hair follicles instead of forming scar tissue. In mouse models, wounds treated with Verteporfin healed with regenerated skin containing functional hair follicles and sebaceous glands. This is striking because mammalian skin normally does not regenerate follicles after wounding. The approach does not involve cell culture or transplantation at all. It manipulates the wound healing environment to trigger follicle formation from resident cells.

Translation to humans remains unproven. Mouse skin heals differently from human skin, and the specific conditions required to replicate this effect in human tissue are not yet established. But the concept of pharmacologically inducing follicle neogenesis in existing skin is compelling and represents a fundamentally different strategy from cell-based approaches.

Companies and organizations to watch

• dNovo Bio (USA): iPSC-to-follicle pipeline. Has raised significant venture funding. Targeting preclinical-to-Phase I transition.
• HairClone (UK): Taking a different commercial approach. They bank (cryopreserve) a patient's DP cells today for future use when multiplication technology matures. This hedges against the possibility that a patient may lose too many healthy follicles by the time the technology arrives.
• Epibiotech (multiple locations): Working on DP cell expansion technology with proprietary culture conditions designed to maintain inductive capacity at scale.
• RIKEN / Organ Technologies (Japan): The Tsuji lab's organoid work has spun out into commercialization efforts, with Japan's regulatory environment potentially allowing faster clinical testing than the FDA pathway.

Realistic timeline assessment

Every five years, someone predicts hair cloning will be available in five years. This pattern has repeated since the early 2000s. Here is a more grounded assessment based on where each approach currently stands.

• Phase I/II clinical trials: The most advanced programs (dNovo, RIKEN-affiliated efforts) could plausibly enter first-in-human or Phase I/II trials within 3-5 years (2029-2031). These trials will test safety and preliminary efficacy in small patient groups.
• Phase III and regulatory approval: Assuming Phase I/II results are positive, Phase III trials would take another 2-4 years. FDA or equivalent regulatory review adds 1-2 years. This puts the earliest possible commercial availability at 7-10 years from now (2033-2036).
• Broad clinical availability: Even after approval, manufacturing scale-up, clinic training, and cost reduction would take additional years. Widespread availability at reasonable cost is likely 10-15 years out.

Cost projections are speculative, but based on comparable regenerative medicine procedures (CAR-T cell therapy, tissue-engineered skin grafts), initial pricing could range from $10,000 to $50,000 per treatment. Prices would likely decrease as manufacturing processes improve and competition increases, but the first generation of hair cloning will almost certainly be expensive.

What this means for you right now

Hair cloning is real science with legitimate prospects. It is not a scam or pure hype. But it is also not something you can wait for if you are losing hair today. Seven to ten years is a long time for androgenetic alopecia to progress unchecked. Follicle miniaturization that advances too far may become difficult to reverse even with future technologies.

The practical approach: use proven treatments now to stabilize your hair and slow or reverse miniaturization. Finasteride, minoxidil, and other established options covered in the hair loss tracking blog can preserve follicles that might otherwise be lost by the time cloning technology arrives. For related experimental approaches that are closer to availability, see the articles on stem cell hair treatments and exosome therapy results.

If you are already on a treatment plan, track your results systematically. Use the hair transplant recovery tracker or the first 90 days tracking plan to build a visual baseline. When hair cloning does become available, you will want a documented history showing where you started, what treatments you used, and how your hair responded. That data will help you and your dermatologist decide whether cloning is necessary or whether existing treatments have already achieved sufficient results.

Frequently asked questions

What is hair cloning?

Hair cloning refers to extracting dermal papilla cells from existing hair follicles, multiplying them in a laboratory, and reimplanting them into bald or thinning scalp to generate new hair follicles. The term "cloning" is somewhat misleading. It does not involve cloning a person. It means expanding the population of hair-inductive cells so that a small biopsy can produce enough cells to restore large areas of hair loss.

When will hair cloning be available?

The most optimistic estimates place first clinical trials at 3-5 years from now, with commercial availability 7-10 years out. Broad, affordable access is likely 10-15 years away. These timelines depend on multiple research programs succeeding in translating laboratory results to human patients, passing regulatory review, and scaling manufacturing.

How much will hair cloning cost?

No one can give a reliable figure because the technology is not yet commercialized. Based on comparable regenerative medicine procedures, initial costs are likely to range from $10,000 to $50,000 per treatment. Prices should decrease over time as manufacturing improves and competition enters the market, similar to how LASIK eye surgery dropped from $10,000+ per eye in the 1990s to $2,000-$4,000 today.

Is hair cloning the same as stem cell therapy?

Not exactly. Hair cloning specifically refers to multiplying dermal papilla cells or creating new follicle-generating cells. Some hair cloning approaches use stem cells (particularly iPSCs) as a starting material, but the terms are not interchangeable. Most current "stem cell" treatments at clinics involve PRP variants or adipose-derived cells, not actual hair follicle cell multiplication. True hair cloning is a more specific and more ambitious goal that remains in the research phase.